This year Medicare will pay for tens of thousands of heart patients t...But a new study finds that while many of these patients will benefit f...In fact the study suggests that if the test were used on the majority...The study published in the January issue of the Journal of the Americ...Each patient received a test called microvolt T-wave alternans or MTWA...

This year, Medicare will pay for tens of thousands of heart patients to have high-tech devices implanted in their chests. Called ICDs or implantable cardioverter defibrillators, the expensive devices are designed to shock damaged hearts back into rhythm and save patients from sudden cardiac death, which kills 300,000 Americans each year.

But a new study finds that while many of these patients will benefit from their ICDs, a large number won't -- and a simple heart-rhythm test can tell who's who.

In fact, the study suggests that if the test were used on the majority of ICD candidates, as many as one-third could be spared the operation to implant a device, without raising their risk of sudden death. That would mean that Medicare could be spared the additional $90,000 lifetime cost of each device compared to best medical therapy.

The study, published in the January issue of the Journal of the American College of Cardiology, is based on data from 768 patients who were candidates for ICDs at Christ Hospital and the Ohio Heart and Vascular Center in Cincinnati. All of the patients had survived heart attacks but had permanent damage to their heart muscle caused by lack of blood flow -- a condition called ischemic cardiomyopathy.

Each patient received a test called microvolt T-wave alternans or MTWA, along with a battery of other tests, during their evaluation. Half of the patients went on to receive ICDs, although the MTWA test results weren't used in the decision-making process. The patients' health and the causes of any deaths were tracked for up to three years.

After that time, the data were analyzed by researchers from the University of Michigan Cardiovascular Center and VA Ann Arbor Healthcare System, in cooperation with the Ohio team.

In all, 67 percent of patients had positive or inconclusive MTWA test results. Of them, the patients who went on to receive an ICD were 55 percent less likely to die in the foll
ow-up period than those who hadn't gotten an ICD. They were also 70 percent less likely to die suddenly due to a heart-rhythm disruption. But at the same time, the one-third of patients who had negative MTWA tests and then received ICDs were no less likely to die than those with similar test results who didn't receive ICDs.

"This is the first study to demonstrate that a subset of patients who meet current criteria for defibrillator placement may not benefit at all from ICDs," says Paul Chan, M.D., M.Sc., senior author and a fellow in cardiovascular medicine at the U-M Medical School. "Use of the MTWA test, which has been covered by Medicare since spring of 2006, could truly help us tell which ICD candidates will benefit most."

In all, the authors calculate, one life could be saved every two years for every nine ICDs implanted in people with positive or inconclusive MTWA results. But it would take 76 ICD implantations in people with negative MTWA tests to save one life every two years.

The reductions in death risk were present even after the authors corrected for many other variables and differences between the two MTWA-positive and MTWA-negative groups.

Chan and his Ohio colleagues, led by first author Theodore Chow, M.D., FACC, of the Lindner Clinical Trial Center at Christ Hospital and the OHVC, have studied the use of MTWA in predicting patients' risk for several years.

Last spring, they published results from the same group of ischemic cardiomyopathy patients, showing that the MTWA test was able to predict the risk of death from any cause, even after they adjusted the data for other heart-rhythm test results and medical issues.

Also in 2006, Chan and his colleagues from U-M and the VA Ann Arbor Health Services Research & Development Center of Excellence demonstrated how MTWA testing could reap hundreds of millions of dollars in savings for the Medicare system, and the taxpayers who support it. T
hat analysis was based on assumptions about MTWA testing's ability to predict risk ?assumptions that can now be adjusted based on the new study results.

This research has focused on patients with ischemic cardiomyopathy ?the most common form of heart-muscle damage that weakens the heart's pumping ability, leaves patients prone to sudden cardiac death and therefore makes them candidates for an ICD.

In recent years, ICDs have been shown to reduce the overall risk of sudden cardiac death well enough to be given approval by the Food and Drug Administration and to receive coverage by Medicare and other insurers.

In fact, in 2004 Medicare expanded the group of patients who were eligible for ICD therapy, leading to estimates that 50,000 new patients each year can qualify for the devices based on criteria relating to their heart rhythm and pumping capability. But if every Medicare participant who qualified for an ICD under current guidelines received one, it would cost the Medicare system an additional $2.9 billion to treat all of them for life.

The use of the MTWA test could potentially save a large part of those costs. But using MTWA testing to determine who will get the most benefit from an ICD is still not standard practice, despite Medicare coverage for one form of the test.

Chan, Chow and their colleagues hope that their study -- and larger studies now under way or planned -- will lead to routine use of MTWA testing, which is much like a standard treadmill "stress test" familiar to many heart patients.

In an editorial accompanying the paper, two University of Pennsylvania cardiologists note that the study adds more information to the issue of MTWA testing for ICD candidates, but that larger studies are needed.'"/>

(Date:12/8/2016)... 8, 2016 Biotheranostics today announced that new ... the Breast Cancer Index (BCI) in identifying which ... most at-risk for disease recurrence and might benefit ... three studies advancing the understanding of the value ... biology and inform decisions related to patient treatment. ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...